BIOCRYST PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements of 5.41 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2026-06-30 was 5.41M shares, a 36.22% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2025-09-30 was 4.66M shares.
- BIOCRYST PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2025-06-30 was 3.97M shares.
- BIOCRYST PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2025 was 3.81M shares.
- BIOCRYST PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2024 was 0.00 shares.
- BIOCRYST PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2023 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 12 month |
|---|---|---|---|---|
| 2026-06-30 | 5.41M shares 10-Q · filed 2026-08-05 | 0.00 shares 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 3.81M shares 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 4.66M shares 10-Q · filed 2025-11-04 | 3.53M shares 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | 3.97M shares 10-Q · filed 2026-08-05 | 2.97M shares 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 1.96M shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 0.00 shares 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-04 | 0.00 shares 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | 0.00 shares 10-Q · filed 2025-08-05 | 0.00 shares 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | 0.00 shares 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |